CN102058659A - Application of palchouli oil in preparing drug for treating bovine mastitis - Google Patents
Application of palchouli oil in preparing drug for treating bovine mastitis Download PDFInfo
- Publication number
- CN102058659A CN102058659A CN 201010623450 CN201010623450A CN102058659A CN 102058659 A CN102058659 A CN 102058659A CN 201010623450 CN201010623450 CN 201010623450 CN 201010623450 A CN201010623450 A CN 201010623450A CN 102058659 A CN102058659 A CN 102058659A
- Authority
- CN
- China
- Prior art keywords
- herba pogostemonis
- oil
- medicine
- drug
- antibiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides application of palchouli oil in preparing a drug for treating the bovine mastitis and also provides a drug composition for treating the bovine mastitis. The drug is used for treating the bovine mastitis, particularly treating clinical mastitis, effectively improving and eliminating a clinical symptom, repairing damaged and infected breast tissue and restoring body immune function, and the drug is proved to be capable of substituting an antibiotic to use because the total effect rate of the drug is superior to the antibiotic integrating pencillin and Mirukang, thereby the problem of bacterial drug resistance caused by extensive use of antibiotics is solved. Moreover, the drug has no influence on bovine liver and kidney functions and the like and short residence time in milk, thereby a harmful effect on food safety caused by antibiotic residue is reduced. Thus, the drug has definite treat and/or prevention effect on the bovine mastitis, is safe, stable and reliable, and provides a novel choice for clinical medication.
Description
Technical field
The present invention relates to the new purposes of oil of Herba Pogostemonis, particularly, is the purposes in the medicine of preparation treatment mammitis of cow.
Background technology
Mammitis of cow is the general name of a mammary gland acinus or a matter inflammation, be that the cattle farm is the most common, control is the most difficult, the highest a kind of disease of cost cost, mastitis not only influences milk yield, causes sizable economic loss, and influence the milk quality, the indirect hazard health.Mammitis of cow is one of three big principal diseases of harm milch cow from find so far more than 150 year always, also is the principal element of restriction dairy sustainable development.It is reported that world's mammitis of cow average attack rate is about 50%, China is 46.4%～85.7%, and wherein the average attack rate of clinic mastitis is 33.41%, and the positive rate of latent mammitis is 73.91%.Estimate that according to the U.S. mastitis council economic loss U.S. that causes every year because of every of mammitis of cow is 225 dollars, Canada is 140 dollars～300 dollars, and the milk yield that the whole world causes every year loses about 3,800,000 tons.The annual loss of every in China is about 1,200～3,600RMB, and the annual according to a preliminary estimate economic loss that causes because of mastitis is also at 700,000,000 yuan～800,000,000 yuan more than.
Mammitis of cow can be divided into clinical type and subclinical type (being commonly referred to latent mammitis) by clinical manifestation, and clinical type can be divided into acute, subacute type and chronic type again.Wherein, acute mastitis is a sudden onset, and breast is rubescent, swelling, hardening, pain, and milk is significantly unusual and reduce, and General Symptoms occurs, sick cattle fervescence, and loss of appetite is ruminated minimizing, pulse speedup, dehydration, asthenia universalis, depressed; The sick cattle of subacute mastitis does not generally have General Symptoms, and the most tangible is that flocculus, grumeleuse are arranged in the milk unusually, and is water sample, and breast has slight heating, swelling and pain; Chronic mammitis is many to be caused by long-time persistent infection, or because acute mastitis is not in time effectively treated and transferred, keeps subclinical type mastitis for a long time, or subclinical type and the alternately appearance of clinical type, the clinical symptoms long-term existence; Subclinical type mastitis claims latent mammitis again, and it is no abnormal to show as the breast and the milk perusal of suffering from cattle, but the milk physicochemical property changes, and the milk somatic number increases, and it is the pathogen carrier that latent mammitis is suffered from cattle, can infect other healthy cattle.(mammitis of cow Prevention Technique guide＜tentative 〉, farming the doctor send out (2010) No. 29)
Traditional Chinese veterinary medicine thinks that mastitis (or mastitis) is an acute mastitis, is that expectorant, wet, gas, blood stagnation knot do not loose, and changes and is scorching; Or be not good at because of feeding and management, the ground that lying on bed for a long time is damp and hot steams on the damp and hot poison, the infringement breast; Or because of excessiveness of stomach-heat, stagnation of QI due to depression of the liver, newborn network lose smooth consequently breast coagulation of QI-blood, the stasis of blood is tied and living carbuncle; Or the nipple that bites when inhaling breast because of calf, evil poison invasion causing carbuncle; Or milk because of suffering from the cattle refusal, milk is stagnated, breast distension etc. and cause primary disease.The research of modern veterinary thinks that mammitis of cow is the result of multifactor comprehensive functions such as pathogenic microorganism, environment, management, is a kind of multi-pathogenesis disease, but former is its main cause of disease with the secondary bacterial infection.Up to now, people have been separated to more than 130 kind of microorganism, usually it is divided into two classes according to its source and circulation way: a class is the contagiousness pathogenic microorganism, it is planted in breast and by milker or milking machine and propagates, and comprises streptococcus agalactiae, streptococcus dysgalactiae, staphylococcus aureus and mycoplasma; Another kind of is environment sexually transmitted disease (STD) substance, comprises escherichia coli, Klebsiella pneumonia, clostridium perfringen, Serratieae, Bacillus proteus, pseudomonas, yeast or fungus, suppurative actinomycetes and Corynebacterium bovis etc.
For the control of mastitis, continue to use antibiotherapy both at home and abroad, and antibiotic problems such as drug residue, bacterial drug resistance and food safety extensive and that life-time service is brought have now caused common people's extensive concern always.Clearly stipulate in " the fresh Lac Bovis seu Bubali of pollution-free food " industry standard of China calendar year 2001 JIUYUE Ministry of Agriculture issue " antibiotic must not detect "; Be defined in again in infant formula, student's breast and the pollution-free food subsequently and must not contain antibiotic; " fresh Lac Bovis seu Bubali acquisition criteria " classified " antibiotic remains " and flavacin M1 as mandatory essential items for inspection in 2004." breast and milk product administration of health way " of issue in 2005 clearly stipulates during the milch cow application antibiotic therapy and the milk in the 5d must not human consumption after the drug withdrawal.Because of there not being the antibiotic succedaneum of effective replacement, still mainly adopt antibiotic that mammitis of cow is prevented and treated at present both at home and abroad, and appearance along with bacterial drug resistance, the therapeutic dose of antibacterials continues to increase in recent years, the treatment number of times increases gradually, and this all obviously prolongs antibacterials residual time in milk.Report part milch cows such as Huang Yijun are still residual in the milk in 6～9d after using antibiotic therapy an antibiotic, causes great hidden danger for food safety.
Complexity in view of this disease cause of disease, the multiformity of pathogenic microorganism kind, a present global bacterial drug resistance difficult problem in addition, the research of nontoxic, noresidue, high-efficiency prevention and control mastitis " antibiotic succedaneum " has become the great industry problem of dairy and milk product secondary industry.How effectively to solve " anti-milk is arranged ", real realize " antibiotic-free milk ", hot issues such as " non-antibiotic therapy and antibiotic effective succedaneum " has but become the task of top priority of development dairy.Chinese medicine is as the product of distinctive theory of Chinese medical science of China and practice, aboundresources, toxic and side effects is little, no hazard residue, be difficult for producing drug resistance, have the characteristics for the treatment of both the principal and secondary aspects of a disease, and have the function of directly killing or suppressing antibacterial and enhancing immunity, at the control mammitis of cow its special advantages is arranged, be expected to become " the antibiotic succedaneum " that prospect and advantage are arranged in the manufacturing green safety food most.
Oil of Herba Pogostemonis derives from the volatile oil of Herba Pogostemonis Pogostemon cablin (Blanco) Benth. or Herba Pogostemonis Agastacherugosa (Fisch.Et Mey.) O.Ktze. extraction, have medical value widely, be usually used in the heat-damp in summer asthenia, uncomfortable in chestly do not relax, cold-damp is closed summer-heat, stomachache vomiting and diarrhoea, nasosinusitis headache, affection of exogenous wind-cold etc.; Modern pharmacological research shows, oil of Herba Pogostemonis has emesis, spasmolytic, calmness, antiallergic and effect such as antibacterial.At present, yet there are no the report that oil of Herba Pogostemonis is used for the treatment of mammitis of cow.
Summary of the invention
Technical scheme of the present invention provides the new purposes of oil of Herba Pogostemonis.The present invention also provides a kind of pharmaceutical composition for the treatment of mammitis of cow.
The invention provides the purposes of oil of Herba Pogostemonis in the medicine of preparation treatment mammitis of cow.
Wherein, described medicine is the medicine of treatment milch cow clinic mastitis.
Further, described medicine is that the clinical type of treatment milch cow is acute, subacute, the medicine of chronic mammitis.
Wherein, described medicine is the medicine of control bovine subclinical mastitis.
Wherein, oil of Herba Pogostemonis of the present invention derives from the volatile oil of Herba Pogostemonis Pogostemon cablin (Blanco) Benth. or Herba Pogostemonis Agastache rugosa (Fisch.Et Mey.) O.Ktze. extraction.
Further preferably, described oil of Herba Pogostemonis derives from the volatile oil that Herba Pogostemonis Pogostemon cablin (Blanco) Benth. extracts, and contains patchouli alcohol in this volatile oil and must not be lower than 26.0%w/w.
The present invention also provides a kind of pharmaceutical composition for the treatment of mammitis of cow, and it is to be active component by oil of Herba Pogostemonis, adds the preparation that acceptable accessories or complementary composition are prepared from; Oil of Herba Pogostemonis prepares by the following method: get Herba Pogostemonis Pogostemon cablin (Blanco) Benth. or Herba Pogostemonis Agastache rugosa (Fisch.Et Mey.) O.Ktze., be ground into coarse powder, the distilled water that adds 10-14 times of weight, soak after 1-5 hour, adopt steam distillation to extract 2-6 hour, promptly get oil of Herba Pogostemonis.
Described preparation is oral formulations, ejection preparation, newborn basin irrigation notes preparation or external preparation, and wherein, newborn basin irrigation is annotated preparation and referred to be applicable to the dabbling all kinds of preparations in newborn pond.
The content of oil of Herba Pogostemonis is 0.1%～100%w/w in the described preparation.
Medicine of the present invention is used for the treatment of mammitis of cow, be applicable to clinic mastitis, particularly acute, subacute, chronic mammitis, can effectively improve and eliminate clinical symptoms, impaired infection mammary gland tissue is repaired, recovered human body immune function, its total effective rate is better than the antibiotic of penicillin and the coupling of lactogenic health, show that medicine of the present invention can substitute antibiotic and use, solve and be extensive use of the bacterial drug resistance difficult problem that antibiotic is brought; And medicine of the present invention does not have influence to functions such as milch cow Liver and kidney, and the residence time in milk is shorter, has reduced the harmful effect that antibiotic remains causes for food safety.In sum, medicine of the present invention has definite treatment and/or preventive and therapeutic effect to mammitis of cow, and safety of medicine is reliable and stable, for clinical application provides a kind of new selection.
The specific embodiment
The preparation of embodiment 1 oil of Herba Pogostemonis of the present invention
Get Herba Pogostemonis medical material (Pogostemon cablin (Blanco) Benth.), pulverized the 20-40 mesh sieve, add the distilled water of 10-14 times of weight, soak after 1-5 hour, adopt steam distillation to extract 2-6 hour, promptly get oil of Herba Pogostemonis of the present invention, wherein contain patchouli alcohol (C
15H
26O) must not be lower than 26.0%.
The preparation of embodiment 2 oil of Herba Pogostemonis of the present invention
Get Herba Pogostemonis medical material (Agastache rugosa (Fisch.Et Mey.) O.Ktze.), pulverized the 20-40 mesh sieve, add the distilled water of 10-14 times of weight, soak after 1-5 hour, adopt steam distillation to extract 2-6 hour, promptly get oil of Herba Pogostemonis of the present invention.
Oil of Herba Pogostemonis of the present invention also can extract according to pharmacopeia (version in 2005) appendix XD determination of volatile oil method, also can adopt organic solvent extraction, supercritical CO
2Prior aries such as extraction are extracted, and perhaps obtain by buying the commercially available prod.The preparation method of 1,2 pairs of oil of Herba Pogostemonis of the present invention of embodiment; should not be construed as is limiting the scope of the invention; all based on above-mentioned technological thought, the modification, replacement, the change that utilize ordinary skill knowledge and customary means to make all belong to scope of the present invention.
Below further prove beneficial effect of the present invention by pharmacodynamics test.
The test of pesticide effectiveness of test example 1 Drug therapy mammitis of cow of the present invention
1. materials and methods
1.1 experimental apparatus
VARIOSKAN Flash (Thermo scientific), milk whole part analyser (Milkscan4200), milk somatic cell analyser (Fossomatic 5000), centrifuge (TDL-60B), step auspicious 1,800 three classification blood counting instruments (BC-1800), COBAS integra 400plus automatic clinical chemistry analyzer.
1.2 reagent
(Bioisystech Co., Ltd is built up in Nanjing to the NAG test kit, lot number: 20091020), Bovine IgGELISA kit (Groundwork Biotechnology Diagnosticate Ltd., lot number: I032-04), Bovine IgA ELISA kit (Groundwork Biotechnology Diagnosticate Ltd., lot number: I0018-04), Bovine IgM ELISA kit (Groundwork BiotechnologyDiagnosticate Ltd., lot number: I033-04).
1.3 trial drug
Experimental drug: embodiment 1 prepares.Positive drug: penicillin (animal pharmaceutical factory of Harbin Pharmaceutical Group produces, product batch number: 080092659), and lactogenic health (lincomycin-neomycin breast injection) (Beijing Hua Sheng pharmaceutcal corporation, Ltd, product batch number: 20090923).
1.4 laboratory animal
The Chinese He Sitan lactating cow of certain cattle farm, Meishan area, Sichuan Province.
1.4.1 experiment grouping
Case is selected: according to the characteristic clinical symptoms of mammitis of cow, by the method for inspection, palpation and inquiring, the sick cattle that is for experiment is satisfied one of following condition and gets final product: ill breast district increases, and inflammatory reaction red, swollen, hot, pain occurs; Breast tissue elasticity reduces, and can find the lump that differs in size during the palpation breast; Milk yield obviously descends even does not have milk, and obvious physical characteristic change appears in milk, ziega or purulent secretion is arranged or be water sample etc., be i.e. clinic mastitis.
Grouping: age-based, parity and in half a year the consistent principles of epidemiology indexs such as morbidity number of times, disease index and clinical symptoms select cases, selected case is divided into invention medicine group and antibiotic group at random, and with healthy cow as the blank group.Blank group: select no any clinical symptoms, do not suffer from 10 of the cattle of clinic mastitis and other disease; Invention medicine group: select to suffer from 19 of the acute attack stage cases of acute mastitis or chronic mammitis, the antibiotic group: 10 of acute attack stage cases selecting to suffer from acute mastitis or chronic mammitis; Wherein the epidemiology situation of antibiotic group and invention medicine group sees Table 1.
Table 1: the epidemiological analysis of clinic mastitis milch cow
Annotate: disease index refers to the light and heavy degree of disease, and wherein state of an illness branch is light, neutralizing weighs Three Estate, " gently " meter 1 minute, " in " counted " weight " meter 3 minutes 2 fens.
1.4.2 medication
(1) blank group: do not give any medicine.
(2) invention medicine group: adopt newborn basin irrigation to annotate and add the administering mode that intramuscular injection combines, wherein newborn basin irrigation is annotated and medicine of the present invention is all used in intramuscular injection.
(3) antibiotic group: adopt intramuscular injection to add newborn basin irrigation and annotate the administering mode that combines.Every cattle intramuscular injection penicillin 1,200 ten thousand unit/time, 2 times/d; Simultaneously newborn basin irrigation is annotated 1/time of lactogenic health, 3 times/d.
Observe the situation of change of inflammatory symptom such as breast is red, swollen, hot, pain and milk and milk yield after invention medicine group and the administration of antibiotic group about 8h, in case sick cow breast inflammation is eliminated, milk yield recovers normal, and it is normal that the color of milk, character etc. are recovered fully, clinically be judged to be recovery from illness, and stop administration.
1.4.3 efficacy determination
Mainly carry out synthetic determination according to the variation of clinical symptoms, milk physicochemical property, milk yield etc., concrete criterion is as follows.Recovery from illness: clinical symptom disappearance such as breast is red, swollen, hot, pain; It is normal that milk color and luster, character, abnormal smells from the patient etc. recover, and it is normal that milk yield is recovered.Produce effects: clinical symptoms such as breast is red, swollen, hot, pain are eliminated and (are contained 2/3) more than 2/3; Milk color and luster, character, abnormal smells from the patient etc. are approaching normal, the milk yield rebound significantly.Effectively: clinical symptoms such as breast is red, swollen, hot, pain are eliminated and (are contained 1/3) more than 1/3; Milk color and luster, character, abnormal smells from the patient etc. alleviate to some extent, and milk yield is gone up to some extent.Invalid: clinical symptoms do not see alleviate or on the contrary the aggravation, the mammary swelling no change; The milk physicochemical character does not have significant change, does not have milk or milk yield and reduces.All cases are all judged curative effect at 6d.
1.5 routine blood test and blood biochemical analysis
Compare with blank, measure the routine blood test situation of change of invention medicine group and the medication of antibiotic group front and back venous blood, and analyze the situation of change of its medication front and back self.The detection index is as follows: leukocyte count (WBC), lymphocyte number (Lymp#), intermediate cell number (Mid#), neutrophilic granulocyte number (Gran#), lymphocyte percentage ratio (Lymp%), intermediate cell percentage ratio (Mid%), neutrophilic granulocyte percentage ratio (Gran%), erythrocyte number (RBC), hemoglobin (HGB), packed cell volume (HCT), mean corpuscular volume (MCV) (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC) (MCHC), Erythrocyte hemoglobin distribution width (RDW), number of platelets (PLT), mean platelet volume (MPV), MPW (PDW), thrombocytocrit (PCT).
Compare with blank, detect invention medicine group and the antibiotic group blood biochemistry index in the serum before and after medication, analyze the situation of change of each group of medication front and back.The detection index is as follows: blood glucose (GLU), blood urea nitrogen (BUN), creatinine (CREA), ALT (ALT), aspartic acid aminotransferase (AST), total protein (TP), albumin (ALB), cholesterol (CHO), triglyceride (TG), total bilirubin (TBIL), alkali phosphatase (AKP), creatine phosphokinase (CK), K
+, Na
+, Cl
-
1.6N-acetyl-β-D-glucosamine glycosides enzyme (NAG) activity and immunoglobulin analysis
Do contrast with the blank group, the situation of change of work of NAG enzyme and immunoglobulin (IgA, IgM, IgG) in mensuration invention medicine group and the antibiotic group medication front and back serum.
1.7 milk protein content analysis
Select newborn physicochemical character to recover normal 4d, 5d and 6d substantially, gather the newborn sample of respectively organizing ill breast district respectively, carry out the comparative analysis of Ruzhong protein content with the milk constituents analyser.
1.8 the retention analysis in milk
Adopt lactic acid bacteria fermentation analysis of experiments invention medicine residual in milk.Normal health milk with not administration is made positive control, gather the milk sample of drug withdrawal 24h, 48h, 60h, 72h, 96h after invention medicine and cured by antibiotics respectively, boil about postcooling to 40 ℃, add 3% Lactobacillus bulgaricus and 1: 1 mixed bacteria of streptococcus thermophilus respectively, 42 ℃ of constant temperature culture 3.5h, the outward appearance and the curdled appearance thereof of observing yoghourt.
1.9 data statistics
Adopt SPSS 17.0 softwares that test data is carried out statistical analysis, the one factor analysis of variance method is adopted in comparative analysis between three groups of its empty group, invention medicine group and the antibiotic groups, independent sample T check is adopted in the relative analysis of invention medicine group and antibiotic group, and pairing T check is adopted in the relative analysis before and after the inherent on the same group treatment.
2 results and analysis
2.1 the effectiveness study of Drug therapy milch cow clinic mastitis of the present invention
2.1.1 clinical curative effect analysis
Use the clinical type mammitis of cow of medicine of the present invention and antibiotic therapy respectively, its clinical efficacy sees Table 2.
Table 2: the invention medicine is treated the efficacy analysis of clinical type mammitis of cow
As seen from the above table, an invention medicine group cure rate and breast district cure rate to the milch cow clinic mastitis in 5d is respectively 89.47% and 88.46%, obvious effective rate is respectively 10.53% and 11.54%, and total effective rate is 100%, slightly is better than the antibiotic group of penicillin and lactogenic health drug combination.Illustrate that medicine of the present invention can be effective to treat the milch cow clinic mastitis.
2.1.2 the time is eliminated in breast district's swelling and treatment time is analyzed
Employing independent sample T check is to invention medicine group and antibiotic group mammary swelling is eliminated the time and treatment time compares analysis, the results are shown in Table 3.
Table 3: the elimination time and the treatment time of breast district's swelling are analyzed
Annotate: treatment time refers to the medication natural law of curing, if cured yet in the 5th day, its treatment time is counted 6 days.
As seen from the above table, the elimination time of invention medicine group breast district's swelling slightly is shorter than the antibiotic group, and treatment time slightly is longer than the antibiotic group, but equal no difference of science of statistics.Illustrate that medicine of the present invention can effectively improve and eliminate the clinical symptoms of milch cow clinic mastitis, unite the therapeutic equivalence of utilization with antibiotic penicillin and lactogenic health.
2.1.3 routine blood test comparative analysis (the results are shown in Instructions Page 9 table 4, table 5)
As shown in Table 4, before treatment, compare with the blank group, invention medicine group neutrophilic granulocyte number and MPW are obviously on the low side (P＜0.05), lymphocyte percentage ratio and intermediate cell percentage ratio obviously higher (P＜0.01), the equal no difference of science of statistics of other index; Antibiotic group RBC number is obviously on the low side (P＜0.05), intermediate cell percentage ratio obviously higher (P＜0.01), the equal no significant difference of other index.Compare with the antibiotic group, invention medicine group RBC number obviously higher (P＜0.05), mean corpuscular is obviously on the low side (P＜0.05), the equal no difference of science of statistics of other index.As shown in Table 5, the erythrocyte number of antibiotic group and invention medicine group (P＜0.05) obviously on the low side, invention medicine group neutrophilic granulocyte percentage ratio (P＜0.01) obviously on the low side, the equal no difference of science of statistics of other index are organized relatively with blank in the treatment back.Compare the equal no difference of science of statistics of all routine blood test indexs of invention medicine group with the antibiotic group.Relatively preceding with treatment, invention medicine group is after medication, though leukocyte decreases no difference of science of statistics, the equal no difference of science of statistics of other all routine blood test indexs.Though treatment back antibiotic group leukocyte decreases no difference of science of statistics, the equal no difference of science of statistics of other routine blood test index.
2.1.4 medication front and back NAG enzyme is lived and the comparative analysis of immunoglobulin content
Employing one factor analysis of variance method is to the blank group in treatment front and back, invention medicine group and antibiotic group serum N AG enzyme is alive and immunoglobulin IgG, IgA and IgM content compare analysis; Adopt pairing T check to invention medicine group and antibiotic group the NAG enzyme before and after medication live and immunoglobulin compares analysis, the results are shown in 6.
Table 6: the comparative analysis of work of NAG enzyme and immunoglobulin content before and after the treatment
Annotate: compare with the blank group,
*P＜0.01.With treatment is relatively preceding on the same group,
★P＜0.05.
Compare with the blank group, the NAG enzyme of invention medicine group and antibiotic group is lived all obviously higher (P＜0.01) before the treatment, and content of immunoglobulin IgG is obviously on the low side (P＜0.01).The NAG enzyme of treatment back invention medicine group and antibiotic group is lived and IgG content returns to normal level, with blank group no difference of science of statistics.Compare with the antibiotic group, invention medicine group is lived and IgG, IgM and the equal no difference of science of statistics of IgA content at forward and backward its NAG enzyme of treatment.And with treatment is relatively preceding on the same group, the invention medicine can make NAG enzyme obviously descend (P＜0.01) alive; IgG content increases to some extent, and IgA and IgM do not have significant change, but equal not statistically significant.Illustrate that medicine of the present invention can make impaired infection mammary gland tissue all be able to obvious reparation, recover the immune function of body to a certain extent, return to normal level substantially, with the antibiotic therapeutic equivalence.
2.1.5 milk protein content analysis
Gather the newborn sample of respectively organizing ill breast district respectively at treatment 4d, 5d and 6d, with milk constituents analysis-e/or determining Ruzhong protein content, between group and group internal protein content compare analysis, the results are shown in Table 7.
Table 7: the comparative analysis of milk protein content
As seen from the above table, compare the equal no difference of science of statistics of protein percentage in 4d, 5d and the 6d milk after Drug therapy of the present invention with time point with the blank group.With the antibiotic group with time point relatively, invention medicine group is at also no difference of science of statistics of the protein percentage of 4d, 5d and 6d.
2.2 the safety research of medicine of the present invention
2.2.1 the blood biochemical analysis of milch cow (the results are shown in Instructions Page 10 table 8, table 9)
As shown in Table 8, before treatment, compare with the blank group, invention medicine group is blank obviously higher (P＜0.05), all the other 16 the equal no difference of science of statistics of blood biochemistry index organized of cholesterol (CHO) only.Antibiotic group only creatine phosphate enzyme (CK) obviously raises (P＜0.05) all the other 16 equal no difference of science of statistics of blood biochemistry index; Compare the equal no difference of science of statistics of all blood biochemistry index of invention medicine group with the antibiotic group.As shown in Table 9, the treatment back is organized relatively with blank, and invention medicine group aspartic acid aminotransferase (AST) obviously raises (P＜0.01), creatine phosphokinase (CK) obviously higher (P＜0.05).Antibiotic group ALT (ALT), K
+Obviously descend (P＜0.01) Na
+Obviously reduce (P＜0.05); Compare invention medicine group aspartic acid aminotransferase (AST), creatine phosphokinase (CK) and Na with the antibiotic group
+Obviously raise (P＜0.05) K
+Obviously raise (P＜0.001).With treatment is relatively preceding on the same group, the equal no difference of science of statistics of treatment back invention medicine all blood biochemistry index of group; The antibiotic group only has albumin (P＜0.05) to occur obviously descending.By overall comparative analysis, medicine of the present invention does not have obvious influence to the blood biochemistry index of milch cow, illustrates that medicine of the present invention does not have obvious influence to functions such as milch cow Liver and kidney, and the treatment that is used for the clinical type of milch cow is comparatively safe.
2.2.2 the retention analysis in milk
Milk sample to 24h, 48h, 72h, 96h after medicine of the present invention and cured by antibiotics drug withdrawal carries out the lactic acid bacteria fermentation test respectively, and the Yoghourt fermentation situation of each time point sees Table 10.
Table 10: the Yoghourt fermentation situation of different withdrawal times
Annotate: "-" refers to that milk is in a liquid state entirely; "+" refers to that 1/3 milk solidifies; " ++ " refers to that 2/3 milk solidifies; " +++" refer to that Yoghourt fermentation is thorough, be curdled appearance entirely.
As seen from the above table, invention medicine group milk sample all has certain solidifying at drug withdrawal 24h and 48h, but solidifies inentirely, and Yoghourt fermentation is thorough during drug withdrawal 72h.And antibiotic group milk sample drug withdrawal 24h and 48h milk do not solidify, and solidify inentirely during drug withdrawal 72h, and Yoghourt fermentation is thorough behind the drug withdrawal 96h.Illustrate that the residence time of Drug therapy clinic mastitis in milk of the present invention is 3 days, 4 days more antibiotic time of staying weak point.
Through evidence, the oil of Herba Pogostemonis for preparing according to embodiment 2 has the effect for the treatment of and/or preventing and treating mammitis of cow too.
In sum, medicine of the present invention can make impaired infection mammary gland tissue be repaired, recover human body immune function, effectively improve and eliminate the clinical symptoms of milch cow clinic mastitis, can be effective to treat mammitis of cow, be specially adapted to the milch cow clinic mastitis, especially acute, subacute and chronic mammitis; And medicine of the present invention does not have influence to functions such as milch cow Liver and kidney, and the residence time in milk is shorter, and is safe and reliable.
Claims (10)
1. the purposes of oil of Herba Pogostemonis in the medicine of preparation treatment mammitis of cow.
2. purposes according to claim 1 is characterized in that: described medicine is the medicine of treatment mammitis of cow.
3. purposes according to claim 2 is characterized in that: described medicine is that the clinical type of treatment milch cow is acute, subacute, the medicine of chronic mammitis.
4. purposes according to claim 1 is characterized in that: described medicine is the medicine of control bovine subclinical mastitis.
5. according to any described purposes of claim 1-4, it is characterized in that: described oil of Herba Pogostemonis derives from the volatile oil of Herba Pogostemonis Pogostemon cablin (Blanco) Benth. or Herba Pogostemonis Agastache rugosa (Fisch.Et Mey.) O.Ktze. extraction.
6. purposes according to claim 5 is characterized in that: described oil of Herba Pogostemonis derives from the volatile oil that Herba Pogostemonis Pogostemon cablin (Blanco) Benth. extracts, and contains patchouli alcohol in this volatile oil and must not be lower than 26.0%w/w.
7. purposes according to claim 5, it is characterized in that: described oil of Herba Pogostemonis prepares by the following method: get Herba Pogostemonis Pogostemon cablin (Blanco) Benth. or Herba Pogostemonis Agastacherugosa (Fisch.Et Mey.) O.Ktze., be ground into coarse powder, the distilled water that adds 10-14 times of weight, soak after 1-5 hour, adopt steam distillation to extract 2-6 hour, promptly get oil of Herba Pogostemonis.
8. pharmaceutical composition for the treatment of mammitis of cow is characterized in that: it is to be active component by oil of Herba Pogostemonis, adds the preparation that acceptable accessories or complementary composition are prepared from.
9. pharmaceutical composition according to claim 8, it is characterized in that: described oil of Herba Pogostemonis prepares by the following method: get Herba Pogostemonis Pogostemon cablin (Blanco) Benth. or Herba Pogostemonis Agastache rugosa (Fisch.Et Mey.) O.Ktze., be ground into coarse powder, the distilled water that adds 10-14 times of weight, soak after 1-5 hour, adopt steam distillation to extract 2-6 hour, promptly get oil of Herba Pogostemonis.
10. it is characterized in that according to Claim 8 or 9 described pharmaceutical compositions: described preparation is that oral formulations, ejection preparation, newborn basin irrigation are annotated preparation or external preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106234508A CN102058659B (en) | 2009-12-28 | 2010-12-28 | Application of palchouli oil in preparing drug for treating bovine mastitis |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910263595.9 | 2009-12-28 | ||
| CN200910263595 | 2009-12-28 | ||
| CN2010106234508A CN102058659B (en) | 2009-12-28 | 2010-12-28 | Application of palchouli oil in preparing drug for treating bovine mastitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102058659A true CN102058659A (en) | 2011-05-18 |
| CN102058659B CN102058659B (en) | 2012-07-04 |
Family
ID=43994284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010106234508A Expired - Fee Related CN102058659B (en) | 2009-12-28 | 2010-12-28 | Application of palchouli oil in preparing drug for treating bovine mastitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102058659B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102743432A (en) * | 2012-07-05 | 2012-10-24 | 成都华神集团股份有限公司 | Application of patchouli oil in preparation of medicines used for treating colpitis |
| CN103223009A (en) * | 2013-05-10 | 2013-07-31 | 成都华神集团股份有限公司 | New uses of Pogostemon cablin oil |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1062171C (en) * | 1997-07-10 | 2001-02-21 | 中山大学 | Application of patchouli oil used as germicide for skin |
-
2010
- 2010-12-28 CN CN2010106234508A patent/CN102058659B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1062171C (en) * | 1997-07-10 | 2001-02-21 | 中山大学 | Application of patchouli oil used as germicide for skin |
Non-Patent Citations (1)
| Title |
|---|
| 《中兽医医药杂志》 20060228 王建国，等 几种植物挥发油的抗菌作用研究 第11-12页 权利要求1-10 , 第1期 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102743432A (en) * | 2012-07-05 | 2012-10-24 | 成都华神集团股份有限公司 | Application of patchouli oil in preparation of medicines used for treating colpitis |
| CN102743432B (en) * | 2012-07-05 | 2014-11-26 | 成都华神集团股份有限公司 | Application of patchouli oil in preparation of medicines used for treating colpitis |
| CN103223009A (en) * | 2013-05-10 | 2013-07-31 | 成都华神集团股份有限公司 | New uses of Pogostemon cablin oil |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102058659B (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102302778A (en) | Preparation method and application of traditional Chinese medicinal immunoglobulin compound preparation | |
| CN106822890A (en) | A kind of pharmaceutical composition for preventing and treating diarrhea of weaned piglets and its preparation method and application | |
| CN102579597B (en) | Chinese herbal compound prescription for preventing and curing mammitis of mammalian livestock and method for preparing same | |
| CN102058659B (en) | Application of palchouli oil in preparing drug for treating bovine mastitis | |
| CN101224279B (en) | Medicine compound for treating urinary infection and preparing method thereof | |
| CN103083510A (en) | Chinese medicinal oral liquid for improving poultry immune function and its preparation method | |
| AU2011101378A4 (en) | Traditional Chinese medicine perfusate for the treatment of dairy cow mastitis and a preparation method thereof | |
| CN104224906A (en) | Traditional Chinese medicine origanum oil emulsion for injection and preparation method of traditional Chinese medicine origanum oil emulsion | |
| CN104739932A (en) | Preparation method of mangnolia officinalis perfusion fluid for dairy cow mastitis | |
| CN106267193A (en) | A kind of for infusion of medicine agent treating bovine mastitis and its preparation method and application | |
| CN108850541A (en) | A kind of feed addictive and preparation method thereof of the alternative antibiotic of disease preventing and treating | |
| CN102614349B (en) | Traditional Chinese medical composition for prevention and treatment of A type clostridiosis welchii, extract, preparation and preparation method and application | |
| CN107375866A (en) | A kind of purposes of Chinese medicine composition in preparing for the somatotrophic medicine of piglet health care | |
| Imam et al. | Anti‐Inflammatory and Antibacterial Potential of Qicao Rukang Powder in Bovine Subclinical Mastitis | |
| CN108740433A (en) | A kind of Chinese herbal feed additive for three inflammation and mastitis for milk cows of sow postpartum | |
| CN104857174A (en) | Preparation method of traditional Chinese medicine micro-ecological oral preparation for preventing and treating staphylococcosis in chickens | |
| CN101209315A (en) | Chinese medicinal injection with antimicrobial and anti-inflammation, milk-smoothing and mass-dissipating efficacy | |
| CN115607614B (en) | Traditional Chinese medicine composition for treating colibacillosis of livestock and poultry and preparation method thereof | |
| CN103800899A (en) | Milk cattle mastitis vaccine | |
| CN108743693A (en) | A kind of piglet health care growth promotion Chinese medicine composition, preparation method and applications | |
| CN103203004B (en) | Medicinal composition with dysentery stopping effect and preparation method thereof | |
| CN112472740B (en) | Chinese herbal medicine compound preparation for preventing and treating cow mastitis and application thereof | |
| CN103494913B (en) | Preparation method of compound radix astragali immune activation injection | |
| CN104873924A (en) | Preparation method of compound micro-ecological preparation effervescent tablets for preventing and treating fowl plague | |
| CN104208136A (en) | Preparation process and using method of sophora alopecuroide alkaloid dairy cow breast injectant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120704 Termination date: 20141228 |
|
| EXPY | Termination of patent right or utility model |